Celldex Therapeutics (CLDX) Stock Price, Quote & News

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 200 7500

Fax: 908 454 1911

Website: www.celldex.com

Address:

Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Timefortendies77 Apr. 13 at 1:45 PM

$CLDX 50-70 Q4, going to be a blockbuster, but just have to wait a bit.

0 · Reply

Merlintrader Apr. 11 at 8:43 AM

$CLDX Celldex Therapeutics ( $CLDX): the full April 2026 deep dive on barzolvolimab, pipeline breadth, financing, competition and what still has to go right https://www.merlintrader.com/celldex-therapeutics-april2026-deepdive/

0 · Reply

Timefortendies77 Apr. 9 at 3:50 PM

$CLDX Offering has closed but no data until Q4, so its just a long waiting period to the EXPLOSION if P3 is great.

1 · Reply

lucabrix Apr. 9 at 3:03 PM

$CLDX Reply!

0 · Reply

lucabrix Apr. 7 at 8:02 PM

$CLDX Celldex Therapeutics 1h We’re pleased to announce the closing of our $345M public offering. This will support the potential commercialization of barzolvolimab, if approved, for the treatment of CSU & the continued advancement of our novel antibody-based pipeline.

0 · Reply

topstockalerts Apr. 3 at 7:57 PM

Celldex Therapeutics Inc priced an underwritten public offering of 10.345M common shares at $29.00 per share, with a 30-day option for underwriters to purchase up to an additional 1.55M shares. Expected gross proceeds are ~$300M before fees and expenses. Closing is anticipated around April 6, 2026, subject to customary conditions. Proceeds, alongside existing cash, will support potential commercialization of barzolvolimab (for chronic spontaneous urticaria, if approved), continued pipeline development, expansion of its bispecific antibody platform, and general corporate purposes. Led by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor Fitzgerald, with LifeSci Capital and H.C. Wainwright & Co. as co-leads. $CLDX

0 · Reply

Arcides Apr. 2 at 10:46 PM

$CLDX held the offering price level today very good.

1 · Reply

OpenOutcrier Apr. 2 at 12:39 PM

$CLDX (-7.5% pre) Celldex prices $300 million stock offering at $29 per share - SI https://ooc.bz/l/97933

0 · Reply

AlertsAndNews Apr. 2 at 2:42 AM

$CLDX CLDX Celldex Announces Pricing of $300 Million Public Offering of Common Stock "today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share."

0 · Reply

DonCorleone77 Apr. 1 at 11:41 PM

$GSAT $PENG $WING $CLDX $ANRO AFTER-HOURS MOVERS: Currently Higher After Earnings: - Franklin Covey (FC) up 11.1% - Penguin Solutions (PENG) up 10.7% Currently Also Higher: - Globalstar (GSAT) up 17.1% after FT reports Amazon is in talks to acquire company - Wingstop (WING) up 2.2% after valuation-driven Piper Sandler upgrade to Overweight Currently Lower After Earnings: - Bassett Furniture Industries (BSET) down 4.9% Currently Also Lower: - Celldex Therapeutics (CLDX) down 3.5% after equity offering - Alto Neuroscience (ANRO) down 8.0% after announcing ALTO-101 did not achieve statistical significance

0 · Reply

Celldex to Present at Upcoming Investor Conference

Apr 6, 2026, 10:53 AM EDT - 10 days ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 1, 2026, 9:48 PM EDT - 15 days ago

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Apr 1, 2026, 4:01 PM EDT - 15 days ago

Celldex Announces Proposed Public Offering of Common Stock

Mar 27, 2026, 10:30 AM EDT - 20 days ago

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Feb 27, 2026, 2:45 PM EST - 6 weeks ago

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Feb 25, 2026, 4:01 PM EST - 7 weeks ago

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Feb 25, 2026, 7:01 AM EST - 7 weeks ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Feb 23, 2026, 8:01 AM EST - 7 weeks ago

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile

Feb 9, 2026, 8:01 AM EST - 2 months ago

Celldex to Present at Upcoming Investor Conferences

Dec 9, 2025, 8:01 AM EST - 4 months ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Nov 10, 2025, 8:01 AM EST - 5 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Sep 17, 2025, 5:11 AM EDT - 7 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep 9, 2025, 9:01 AM EDT - 7 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 20, 2025, 10:22 AM EDT - 8 months ago

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Aug 19, 2025, 4:01 PM EDT - 8 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 14, 2025, 10:48 AM EDT - 10 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 12, 2025, 6:01 PM EDT - 11 months ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 10, 2025, 4:01 PM EDT - 11 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 6, 2025, 8:01 AM EDT - 11 months ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

May 8, 2025, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 4:01 PM EDT - 1 year ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Mar 4, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Dec 19, 2024, 8:01 AM EST - 1 year ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Nov 20, 2024, 8:01 AM EST - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 6, 2024, 4:01 PM EST - 1 year ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 26, 2024, 5:43 PM EDT - 1 year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 2 years ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 2 years ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 6, 2024, 4:01 PM EDT - 2 years ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 17, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 2 years ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 29, 2024, 9:14 PM EST - 2 years ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 2 years ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 26, 2024, 7:01 AM EST - 2 years ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 24, 2024, 2:05 PM EST - 2 years ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 6, 2024, 4:01 PM EST - 2 years ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:01 AM EST - 2 years ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Timefortendies77 Apr. 13 at 1:45 PM

$CLDX 50-70 Q4, going to be a blockbuster, but just have to wait a bit.

0 · Reply

Merlintrader Apr. 11 at 8:43 AM

0 · Reply

Timefortendies77 Apr. 9 at 3:50 PM

$CLDX Offering has closed but no data until Q4, so its just a long waiting period to the EXPLOSION if P3 is great.

1 · Reply

lucabrix Apr. 9 at 3:03 PM

$CLDX Reply!

0 · Reply

lucabrix Apr. 7 at 8:02 PM

0 · Reply

topstockalerts Apr. 3 at 7:57 PM

0 · Reply

Arcides Apr. 2 at 10:46 PM

$CLDX held the offering price level today very good.

1 · Reply

OpenOutcrier Apr. 2 at 12:39 PM

$CLDX (-7.5% pre) Celldex prices $300 million stock offering at $29 per share - SI https://ooc.bz/l/97933

0 · Reply

AlertsAndNews Apr. 2 at 2:42 AM

0 · Reply

DonCorleone77 Apr. 1 at 11:41 PM

0 · Reply

shuffle13 Apr. 1 at 8:43 PM

$CLDX wondering how much will it be for-blank form filling

0 · Reply

JasonCO Apr. 1 at 8:18 PM

$CLDX bums

0 · Reply

DonCorleone77 Apr. 1 at 8:14 PM

$CLDX Celldex announces common stock offering, no amount given Celldex Therapeutics announced that it has commenced an underwritten public offering for the sale of shares of its common stock. Celldex currently intends to use the net proceeds of this offering, together with its existing cash, cash equivalents, and marketable securities, (i) to fund ongoing commercial readiness activities and the commercial launch of barzolvolimab, if approved, for the treatment of CSU in the United States, (ii) to continue the clinical and preclinical development of its product candidates, including current and future development of barzolvolimab, (iii) to grow its bispecific antibody platform and clinical candidates, (iv) to fund ongoing efforts to develop additional clinical pipeline product candidates and (v) for general corporate purposes. Leerink Partners and TD Cowen are acting as joint bookrunning managers for the proposed offering.

0 · Reply

lucabrix Mar. 31 at 3:52 PM

$CLDX Reply!!!

0 · Reply

Steve1545 Mar. 30 at 1:12 PM

$CLDX

0 · Reply

laaarsas Mar. 28 at 1:58 PM

$CLDX What do ppl see as main risk here? I see that we don't have data for omali-refractory pts, only company says effect is similar as to rest of study population. Also we don't know how many omali-refr pts there will be in EMBARQ. What are mains risks you see here?

1 · Reply

laaarsas Mar. 28 at 1:08 PM

$CLDX What is wibe like in here?

0 · Reply

free2dream Mar. 25 at 1:40 PM

$CLDX market has not noticed $CLDX yet. Barzolvolimab will be a dupixent competitor , $20B annual sales , undiscovers like $LITE at $30 last year

1 · Reply

lucabrix Mar. 23 at 4:49 PM

$CLDX 200$ in 2027!

0 · Reply

topstockalerts Mar. 23 at 2:09 PM

$CLDX biotech that periodically gets attention around clinical pipeline developments. If headlines drop, volatility can expand quickly.

0 · Reply

notreload_ai Mar. 23 at 1:25 PM

Wolfe Research upgrades $CLDX to Outperform from Peer Perform, citing stronger 2026 catalysts and depressed valuation for rebound potential. https://notreload.xyz/wolfe-research-turns-bullish-on-celldex-upgrading-to-outperform/

0 · Reply

Steve1545 Mar. 23 at 12:42 PM

$CLDX

0 · Reply

Market Cap	2.25B
Revenue (ttm)	1.55M
Net Income (ttm)	-258.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-16,694.19%
Debt to Equity Ratio	0.00

Volume	853,100
Avg Vol	1,101,402
Day's Range	N/A - N/A
Shares Out	66.57M
Stochastic %K	89%
Beta	1.19
Analysts	Strong Sell
Price Target	$55.50